Lithium Remains the Gold Standard for Bipolar I Disorder in Adults
Lithium continues to be the gold standard treatment for bipolar I disorder in adults, particularly for maintenance therapy and prevention of manic episodes, though it now shares first-line status with other mood stabilizers and atypical antipsychotics depending on the clinical phase and patient characteristics.
FDA-Approved Status and Clinical Position
Lithium holds unique regulatory standing as the only medication FDA-approved for both acute mania and maintenance therapy in bipolar disorder 1. The FDA label explicitly states lithium is indicated for "treatment of manic episodes of Bipolar Disorder" and "maintenance treatment for individuals with a diagnosis of Bipolar Disorder," where it "reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occur" 1.
Current Treatment Framework
For acute mania, standard therapy includes lithium, valproate, and/or atypical antipsychotic agents as first-line options 2. The choice should be based on:
- Evidence of efficacy for the specific phase of illness
- Presence of confounding features (rapid cycling, psychotic symptoms)
- Side effect profile and safety considerations
- Patient's medication history and family response patterns
- Patient and family preferences 2
Evidence for Lithium's Continued Primacy
Recent systematic analyses confirm lithium's enduring position. A 2024 review analyzing 59 clinical studies over 7 years concluded that lithium remains "the gold standard drug in the treatment of bipolar disorder" and is "the only drug that is effective in the prophylaxis of manic, depressive, and suicidal symptoms" 3. This is particularly significant because lithium demonstrates efficacy across all phases of bipolar disorder—a profile unmatched by other agents 4, 3.
The 2018 update on long-term efficacy reinforces that "lithium has been the gold standard in the long-term treatment of bipolar disorders" for over 40 years and recent research indicates it "is still the first-line treatment in this indication" 5. A 2005 comprehensive review similarly concluded that "lithium remains the gold standard for overall preventative efficacy in bipolar disorder, especially to decrease manic or hypomanic relapse" 6.
Comparative Efficacy Data
When directly compared to alternatives, lithium demonstrated superiority to aripiprazole, valproic acid, and quetiapine in improving manic symptoms 3. Lithium therapy resulted in lower relapse rates compared to valproic acid and showed greater neuroprotective effects than quetiapine 3. A 2026 randomized trial found that lithium combined with quetiapine achieved significantly greater YMRS score reductions than standard dosing approaches 7.
The Evolving Treatment Landscape
Important caveat: While lithium maintains gold standard status, clinical practice has shifted toward combination therapy as the standard of care. The evidence shows that "any monotherapy for use as a maintenance therapy of bipolar disorder appears to be inadequate for long-term use in the management of the majority of patients" 6. Most patients eventually require concomitant treatment to maintain full remission 6.
WHO guidelines from 2011 recommend that "lithium, valproate, or carbamazepine should be offered to individuals with bipolar mania" and "lithium or valproate should be used for the maintenance treatment of bipolar disorder" 8. This reflects the reality that multiple first-line options now exist, though lithium retains special status.
Clinical Specificity and Patient Selection
Lithium works best in patients with "classic" bipolar disorder—those with clear episodic patterns, particularly euphoric mania without rapid cycling or mixed features 9. When patients are selected according to this characteristic clinical profile rather than just a bipolar diagnosis, lithium continues demonstrating superior efficacy compared to all other available psychiatric medications 10.
The decline in lithium use across many countries stems largely from "insufficient understanding of lithium's clinical uses" rather than true limitations of the medication 10. After sufficient clinician and patient education regarding lithium stabilization principles, monitoring requirements stop being burdensome 10.
Monitoring and Safety Considerations
The FDA label specifies that lithium requires careful monitoring, particularly in patients with renal or cardiovascular disease 1. Baseline assessment should include complete blood counts, thyroid function tests, urinalysis, BUN, creatinine, serum calcium, and pregnancy testing in females 2. Once stable, lithium levels and renal/thyroid function should be monitored every 3-6 months 2.
For older adults (≥60 years), age-adjusted therapeutic ranges are essential. A 2026 systematic review found that mean lithium levels of 0.47-0.67 mmol/L were effective in older adults, while levels of 0.82-1.00 mmol/L increased side effects and 1.20-1.25 mmol/L were overtly toxic 11. Age-related reduction in renal clearance necessitates lower therapeutic targets in this population 11.
Practical Implementation Strategy
The optimal approach: Use lithium (potentially combined with an atypical antipsychotic if necessary) from the start for acute manic episodes. Once remission is achieved and euthymia maintained during continuation treatment, taper the atypical antipsychotic if possible and continue lithium as monotherapy for prophylactic treatment 5. This strategy aligns lithium use with the strongest scientific evidence for long-term bipolar disorder management 5.
Key Limitations
The major challenge remains predicting who will respond to and tolerate lithium prophylactically 5. Additionally, among lithium-responsive patients, glomerular filtration rate decline can develop after decades of continuous administration, though other adverse effects are typically mild and clinically manageable 10.